The present invention pertains to a method for determination of the significance of a histologically detected premalignant lesion as a risk for intestinal type gastric cancer or carcinoma in situ, comprising detecting from a patient sample comprising gastric mucosa cells a) cyclooxygenase-2 Cox-2) mRNA expression, or b) Cox-2 protein; wherein overexpression of Cox-2 is indicative of an increased risk for intestinal type gastric cancer.
|Publication Year||9 Jul 2002|
|Publication status||Published - 9 Jul 2002|
|MoE publication type||H1 Granted patent|
Fields of Science
- 312 Clinical medicine